Want to see NTRA full AI Analyst Report?
NTRA Stock Chart & Stats
$208.40
$1.33(0.78%)
At close: 4:00 PM EST
$208.40
$1.33(0.78%)
Day’s Range― - ―
52-Week Range$131.81 - $288.04
Previous CloseN/A
Volume352.74K
Average Volume (3M)1.46M
Market Cap
$38.26B
Enterprise Value$27.45K
Total Cash (Recent Filing)$1.09B
Total Debt (Recent Filing)$240.08M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Jul 30, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.63
Shares Outstanding143,215,380
10 Day Avg. Volume1,146,846
30 Day Avg. Volume1,464,250
Financial Highlights & Ratios
PEG Ratio230.60
Price to Book (P/B)18.29
Price to Sales (P/S)13.58
P/FCF Ratio287.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$281.19Price Target Upside34.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)-1.62
Revenue Forecast (FY)$2.80B
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationNatera has moved to materially positive cash generation, with TTM operating cash flow ~ $211M and FCF ~ $92M. Durable positive cash flow improves runway for R&D and commercial expansion, reduces refinancing risk, and supports reinvestment without relying solely on equity raises.
Strong Revenue And Unit GrowthBroad-based volume and revenue acceleration — including record quarterly revenue and a >1M annualized MRD run rate — indicate scalable demand for Signatera and women's health products, strengthening durable revenue growth as adoption and clinician reliance expand.
High Gross Margins And Raised GuidanceSustained gross margins near 65% reflect favorable unit economics for molecular assays and operating leverage as volumes scale. Management's upward margin and revenue guidance signals structural improvement in profitability potential beyond transient quarter timing effects.
Bears Say
Ongoing Net Losses / Negative ROEDespite revenue scale and margins, the company remains unprofitable with negative EBIT and ROE, meaning it still must convert margin strength into sustained operating profits. Persistent losses can constrain long-term returns and limit capital allocation flexibility if not corrected.
Payer Coverage & Prior-authorization FrictionIncomplete Medicare/commercial coverage and prior-authorization hurdles can structurally slow adoption and cash realization for diagnostic tests. Ongoing payer work increases revenue uncertainty and can cap addressable volume growth until reimbursement expands.
Equity Plan Increase May Dilute ShareholdersApproval to expand the equity award pool supports retention but introduces dilution risk to existing holders. Over multiple grant cycles, expanded share issuance can offset EPS gains from revenue growth and complicate long-term per-share value accretion.
Natera News
NTRA FAQ
What was Natera Inc.’s price range in the past 12 months?
Natera Inc. lowest stock price was $131.81 and its highest was $288.04 in the past 12 months.
What is Natera Inc.’s market cap?
Natera Inc.’s market cap is $38.26B.
When is Natera Inc.’s upcoming earnings report date?
Natera Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 6 days.
How were Natera Inc.’s earnings last quarter?
Natera Inc. released its earnings results on May 07, 2026. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.542 by -$0.058.
Is Natera Inc. overvalued?
According to Wall Street analysts Natera Inc.’s price is currently Undervalued.
Does Natera Inc. pay dividends?
Natera Inc. does not currently pay dividends.
What is Natera Inc.’s EPS estimate?
Natera Inc.’s EPS estimate is -0.49.
How many shares outstanding does Natera Inc. have?
Natera Inc. has 143,215,380 shares outstanding.
What happened to Natera Inc.’s price movement after its last earnings report?
Natera Inc. reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.542. Following the earnings report the stock price went down -11.637%.
Which hedge fund is a major shareholder of Natera Inc.?
Currently, no hedge funds are holding shares in NTRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Natera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$281.19 (34.93% Upside)
$281.19 (34.93% Upside)
Blogger Sentiment
Bearish
NTRA Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 450.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 15.4%
Last 30 Days ▲ 15.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
88.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
50.91%
Trailing 12-Months
Company Description
Natera Inc.
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
NTRA Stock 12 Month Forecast
Average Price Target
$281.19
▲(34.93% Upside)
Technical Analysis
Ownership Overview
3.04% Insiders
34.30% Mutual Funds
0.81% Other Institutional Investors
45.75% Public Companies and
Individual Investors